Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milademetan + Quizartinib in FLT3-ITD+ AML
NCT03552029Phase 1Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of milademetan in acute myeloid leukemia (AML) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of Participants With Dose Limiting Toxicities at 28 days and Number of Participants With Any Treatment-emergent Adverse Events. Started Dec 2018; status: terminated.
02
Drugs
milademetan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03552029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552029.